1. Home
  2. GOAI vs BMEA Comparison

GOAI vs BMEA Comparison

Compare GOAI & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eva Live Inc. Common Stock

GOAI

Eva Live Inc. Common Stock

N/A

Current Price

$1.66

Market Cap

89.9M

Sector

Technology

ML Signal

N/A

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.34

Market Cap

95.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GOAI
BMEA
Founded
2015
2017
Country
United States
United States
Employees
N/A
37
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
89.9M
95.7M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
GOAI
BMEA
Price
$1.66
$1.34
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$9.83
AVG Volume (30 Days)
195.5K
446.5K
Earning Date
04-10-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
966.67
69.19
EPS
N/A
N/A
Revenue
$17,037,328.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
82.59
N/A
52 Week Low
$1.42
$0.87
52 Week High
$6.67
$2.99

Technical Indicators

Market Signals
Indicator
GOAI
BMEA
Relative Strength Index (RSI) 30.63 56.49
Support Level N/A $1.21
Resistance Level $2.68 $1.44
Average True Range (ATR) 0.16 0.06
MACD 0.01 0.01
Stochastic Oscillator 37.10 96.77

Price Performance

Historical Comparison
GOAI
BMEA

About GOAI Eva Live Inc. Common Stock

Eva Live Inc is a United States-based technology company that has developed an automated and intelligent advertiser campaign management platform, Eva Platform, which enables advertisers ('customers, clients') to buy advertising space on several digital channels to reach their desired audience. The company also works with Businesses that utilize its in-house digital marketing capabilities, including advice, creative services, account management, production of advertising materials, media planning, and buying.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Share on Social Networks: